Cervical Cancer Screening Every 5 Years with Pap and HPV Testing
Yes, for an average-risk woman aged 30-65 with previously normal results and no history of cervical dysplasia, Pap smear combined with high-risk HPV testing (cotesting) every 5 years is appropriate and represents the preferred screening strategy according to multiple major guidelines. 1
Recommended Screening Strategy
The American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology jointly recommend the following for women aged 30-65 years 1, 2:
Preferred approach:
- Cotesting (HPV + cytology) every 5 years
Acceptable alternative:
- Cytology alone every 3 years
The U.S. Preventive Services Task Force similarly endorses both strategies as acceptable, though they do not designate cotesting as "preferred" 3, 4.
Evidence Supporting 5-Year Intervals
The rationale for extending screening intervals to 5 years with cotesting is robust:
Women who test negative for both HPV and cytology constitute an exceptionally low-risk group with a cumulative 5-year risk of CIN2+ of only 0.34% 3
A large U.S. cohort study of 330,000 women demonstrated that the 5-year cumulative incidence of cervical cancer in HPV-negative, cytology-negative women was 3.2 per 100,000 - substantially lower than cytology alone (7.5 per 100,000) 5, 6
The estimated average time for high-grade precancerous lesions to progress to invasive cancer is 10 years, providing ample opportunity for detection even with 5-year intervals 3
Important Caveats and Pitfalls
Annual screening is explicitly NOT recommended at any age with any screening method 1, 2. Too-frequent screening leads to:
- Higher false-positive rates
- Unnecessary colposcopies and biopsies
- Overtreatment of lesions likely to regress
- Minimal additional benefit in cancer prevention
These recommendations apply ONLY to average-risk women. They do NOT apply to 1, 7:
- Women with history of cervical cancer or CIN2+
- Immunocompromised women (HIV, transplant, chronic steroids)
- Women exposed to diethylstilbestrol in utero
- Women with inadequate prior screening history
Special consideration for women with prior high-grade lesions: Women with a history of CIN2, CIN3, or adenocarcinoma in situ should continue routine screening for at least 20 years after treatment, even if this extends screening past age 65 1, 7.
Evolving Guidelines
Note that the 2020 ACS guideline update 8 now recommends primary HPV testing alone every 5 years starting at age 25 as the preferred strategy, with cotesting or cytology alone as acceptable alternatives where primary HPV testing is unavailable. However, the 2012-2019 guidelines 1 that established cotesting every 5 years remain widely implemented and appropriate for your patient scenario.
When to Stop Screening
Screening should discontinue after age 65 if the patient has 1, 5, 4:
- 3 consecutive negative cytology results OR
- 2 consecutive negative cotest results
- Within the 10-year period before cessation
- With the most recent test within the last 5 years
Once discontinued, screening should not resume for any reason, including new sexual partners 1.